The molecular phenotype of female Cdkl5E364X mice also suggests that two novel druggable targets, Gabra1 and Gabra5, warrant further exploration as potential anti-epileptic therapies for CDD in future studies. This evidence concerns the gene GABRA1 and craniodiaphyseal dysplasia.